Testing an HIV vaccine and antibody combo for treatment-free control
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study tests a combination of an HIV vaccine and an antibody infusion to see if your immune system can control HIV without daily pills. You would temporarily stop your HIV medication under close monitoring and restart if needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a Thai national, aged 18 to 60, and able to read and write Thai.
- You must have started HIV treatment (ART) very early after infection and stayed on it without major breaks for at least 48 weeks.
- Your HIV viral load must be undetectable (below 50 copies/mL) for at least 48 weeks.
- Your CD4 count (immune cell count) must be 400 or higher, and you must be in good general health.
- You must be willing to take a short break from your HIV treatment (supervised by the study team) and to restart it as needed.
- You must be willing to use effective contraception (if applicable) and follow study rules about sexual activity.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving special HIV-fighting antibodies along with starting standard HIV medicine soon after infection can help you reach “HIV remission.” It may reduce or delay the return of detectable virus, but you must be willing to follow close monitoring and specific study steps.
This study tests whether a combination of special antibodies (bNAbs) can help control HIV without daily medication. It involves several steps and is for children who are already doing well on ART.
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
This study tests a new injectable drug (VH4011499) for safety and how the body processes it. It's for healthy adults without HIV, and participants will get either the study drug or a placebo (an inactive shot).
This trial tests a combination of an HIV vaccine and a new antibody treatment (GS-2872) to see if it can help control HIV without daily pills. It is for people with well-controlled HIV who are looking for ways to reduce their dependence on antiretroviral therapy.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.